The enrichment in our study can largely be explained by the fact that, as a reference centre, aggressive and MYC+ DLBCL cases (including suspected cases of Burkitt lymphoma which subsequently prove to be MYC+ DLBCL) are referred to our site. This evidence concerns the gene MYC and Burkitt lymphoma.